[Renin-angiotensin-aldosterone system and fibrinolysis].
Experimental, genetic and clinical evidence suggests that the renin-angiotensin-aldosterone system (RAAS) may participate in the pathogenesis of thromboembolic cardiovascular disorders such as coronary heart disease. This interrelationship may involve mechanisms other than changes in arterial blood pressure. In addition to various possible interactions, accumulating evidence suggests that the RAAS is involved in the regulation of the fibrinolytic system. Several recent studies have shown that stimulation of the RAAS may be associated with an activation of plasminogen activator inhibitor 1 (PAI-1). Since profibrinolytic factors (especially tissue plasminogen activator [t-PA]) remain unchanged, increased activity of the RAAS may thus alter the fibrinolytic balance towards a decreased fibrinolytic activity. These findings may be of special importance for a variety of clinical problems such as the long-term effect of a low NaCl-intake on cardiovascular morbidity and mortality and the possible value of drugs indirectly or directly interfering with the RAAS such as diuretics, ACE-inhibitors and angiotensin II Type 1 (AT1) receptor antagonists.
Lottermoser
K
K
Medizinische Universitäts-Poliklinik, Universität Bonn.
Hertfelder
H J
HJ
Vetter
H
H
Düsing
R
R
D000450:Aldosterone / Q000502:physiology*; D000818:Animals; D003328:Coronary Thrombosis / Q000097:blood; D005342:Fibrinolysis / Q000502:physiology*; D006801:Humans; D012084:Renin-Angiotensin System / Q000502:physiology*; D012307:Risk Factors
D000450:Aldosterone
Renin-Angiotensin-Aldosteron-System und Fibrinolyse.